Format

Send to

Choose Destination
J Med Chem. 2016 May 26;59(10):4459-61. doi: 10.1021/acs.jmedchem.6b00550. Epub 2016 Apr 27.

An Advanced Tool To Interrogate BRD9.

Author information

1
Drug Discovery Department, Moffitt Cancer Center , Tampa, Florida 33612, United States.
2
Department of Molecular Medicine, University of South Florida , Tampa, Florida 33612, United States.

Abstract

Selective inhibitors of bromodomain-containing protein 9 (BRD9) may have therapeutic potential in the treatment of human malignancies and inflammatory diseases. A selective small molecule inhibitor that is well tolerated and has proper pharmacokinetic properties is required to explore the function of BRD9 in diseases. BI-9564 (2) is a cell permeable and noncytotoxic BRD9 inhibitor provided to the scientific community to explore BRD9 biology and determine its potential as a drug target.

PMID:
27120693
DOI:
10.1021/acs.jmedchem.6b00550
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center